Compare Cytokinetics Inc (CYTK) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ON Holding AG — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while ON Holding AG trades at $37.74 (market cap $12.58B). The key difference: Cytokinetics Inc and ON Holding AG are close in size by market cap, and Cytokinetics Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| CYTK | ONON | |
|---|---|---|
Market Cap | $11.12B | $12.58B |
Sector | Technology | Technology |
52-Week High | $87.26 | $54.24 |
52-Week Low | $33.23 | $31.88 |
Enterprise Value | $11.59B | $11.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
ONON trades at $37.92, down 1.61% today, with a bullish technical trend and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue reached $3.01B in 2025, with gross margins at 63.88% and net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy and a consensus price target of $47.33.
Outlook remains favorable given robust growth and margin expansion, but risks include high valuation multiples and competitive pressures. The stock offers upside potential if execution continues, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
